Literature DB >> 910712

Provocation of coronary spasm with ergonovine maleate. New test with results in 57 patients undergoing coronary arteriography.

J S Schroeder, J L Bolen, R A Quint, D A Clark, W G Hayden, C B Higgins, L Wexler.   

Abstract

Ergonovine maleate (Ergotrate) was given to 57 patients undergoing coronary arteriography for investigation of angina occurring at rest or without provocation when routine study showed normal arteries or insufficient occlusive disease to explain their symptoms. This provocative test induced coronary arterial spasm in 13 patients, 10 of whom had definite Prinzmetal's angina. The spasm was easily reversed with sublingually administered nitroglycerin. The spasm was occlusive or nearly occlusive in nine patients, and there was associated reproduction of the chest pain and S-T elevation similar to the spontaneous episodes. One patient with Prinzmetal's angina had S-T depression rather than elevation in association with the chest pain. The other three patients without Prinzmetal's angina had focal narrowing without coronary occlusion, reproduction of the chest pain or electrocardiographic changes. Of the 44 patients who did not demonstrate coronary spasm in response to ergonovine, 29 had normal coronary arteries and 15 had various degrees of atherosclerotic occlusive disease. We conclude that cautious administration of ergonovine maleate during coronary arteriography can be safely used to elicit coronary spasm in some patients who have insufficient fixed occlusive disease to explain their symptoms.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 910712     DOI: 10.1016/0002-9149(77)90060-1

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  29 in total

1.  Radionuclide and angiographic evidence of right coronary artery spasm.

Authors:  D Hsi; G Bhagwath; M Cotto
Journal:  J Nucl Cardiol       Date:  2001 Jan-Feb       Impact factor: 5.952

Review 2.  Chest pain of esophageal origin.

Authors:  A K Rustgi; S Chopra
Journal:  J Gen Intern Med       Date:  1989 Mar-Apr       Impact factor: 5.128

3.  123I-MIBG myocardial scintigraphy as a noninvasive screen for the diagnosis of coronary artery spasm.

Authors:  J W Ha; J D Lee; Y Jang; N Chung; J Kwan; S J Rim; Y J Lee; W H Shim; S Y Cho; S S Kim
Journal:  J Nucl Cardiol       Date:  1998 Nov-Dec       Impact factor: 5.952

4.  Relation of basal coronary tone and vasospastic activity in patients with variant angina.

Authors:  Y Ozaki; D Keane; P W Serruys
Journal:  Heart       Date:  1996-03       Impact factor: 5.994

5.  Unusual vasomotor coronary arterial responses after reversal of ergonovine induced spasm with glyceryl trinitrate.

Authors:  R Hattori; Y Takatsu; Y Yui; H Nonogi; C Kawai
Journal:  Br Heart J       Date:  1984-03

6.  Mechanisms of ergonovine-induced hyperconstriction of coronary artery after x-ray irradiation in pigs.

Authors:  S Egashira; W Mitsuoka; H Tagawa; T Kuga; H Tomoike; M Nakamura; A Takeshita
Journal:  Basic Res Cardiol       Date:  1995 Mar-Apr       Impact factor: 17.165

7.  Ergonovine-induced constrictions of epicardial coronary arteries in conscious dogs: alpha-adrenoceptors are not involved.

Authors:  J Holtz; W Held; O Sommer; G Kühne; E Bassenge
Journal:  Basic Res Cardiol       Date:  1982 May-Jun       Impact factor: 17.165

8.  Coronary and peripheral arterial responses to ergometrine in patients susceptible to coronary and oesophageal spasm.

Authors:  J J Dalal; A M Dart; H A Davies; D J Sheridan; M S Ruttley; A H Henderson
Journal:  Br Heart J       Date:  1981-02

9.  Prinzmetal's angina with documented coronary artery spasm. Treatment and follow-up.

Authors:  V F Huckell; P R McLaughlin; J E Morch; E D Wigle; A G Adelman
Journal:  Br Heart J       Date:  1981-06

10.  Atherosclerosis influences the vasomotor response of epicardial coronary arteries to exercise.

Authors:  J B Gordon; P Ganz; E G Nabel; R D Fish; J Zebede; G H Mudge; R W Alexander; A P Selwyn
Journal:  J Clin Invest       Date:  1989-06       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.